Harms outweigh benefits of COX 2 for many patientsBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7389.0/f (Published 15 March 2003) Cite this as: BMJ 2003;326:f
Question How safe are COX 2 inhibitors?
Synopsis This is an excellent (although non-systematic) review of the benefits and harms of COX 2 inhibitors. It is non-systematic because we aren't given details of the author's search strategy or inclusion criteria, and he only really discusses the two large COX 2 trials (VIGOR for rofecoxib and CLASS for celecoxib). Nevertheless, these two studies are the 800 pound gorillas in this area, and the author took advantage of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial